Evaluation of Anticancer Efficacy of Survivin Si-RNA Functionalized Combined Drug-loaded Mesoporous Silica Nanoparticles in a Lung Cancer Mouse Model

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Date 2025 Jan 8

PMID 39777536

Authors

Fahima Dilnawaz

Sarita Jena

Sunita Nayak

Affiliations

Soon will be listed here.

Abstract

Lung cancer continues to be the leading cause of mortality globally. Nanotechnology-mediated targeted drug delivery approach is one of the promising strategies for the treatment of lung cancer. Due to their multifactorial role, mesoporous silica nanoparticles (MSNs), have attracted a lot of attention for drug delivery. The emerging dual-drug co-delivery approach has drawn much attention due to circumventing various drug-resistant mechanisms in tumor cells. Further, functionalization of si-RNA (survivin) to the dual drugs (etoposide plus carfilzomib) or (docetaxel plus carfilzomib) loaded MSNs can be a potential tool to inhibit gene expression specifically. In the present study, we investigated the comparative therapeutic efficacy of co-delivered anticancer drugs functionalized with survivin siRNA in MSNs for lung cancer. According to our findings, this kind of combination therapy has inhibited the function of the survivin protein while promoting increased therapeutic efficacy due to synergistic pharmacological activity, and found si-RNA- (etoposide plus carfilzomib) to be a better candidate for lung cancer treatment in the future.

References

Agarwal K, Mukherjee A, Sen S . Etoposide (VP-16): cytogenetic studies in mice. Environ Mol Mutagen. 1994; 23(3):190-3. DOI: 10.1002/em.2850230307. View

Bade B, Dela Cruz C . Lung Cancer 2020: Epidemiology, Etiology, and Prevention. Clin Chest Med. 2020; 41(1):1-24. DOI: 10.1016/j.ccm.2019.10.001. View

Bukowski K, Kciuk M, Kontek R . Mechanisms of Multidrug Resistance in Cancer Chemotherapy. Int J Mol Sci. 2020; 21(9). PMC: 7247559. DOI: 10.3390/ijms21093233. View

Carneiro B, El-Deiry W . Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020; 17(7):395-417. PMC: 8211386. DOI: 10.1038/s41571-020-0341-y. View

Carvalho G, Marena G, Karnopp J, Jorge J, Sabio R, Martines M . Cetyltrimethylammonium bromide in the synthesis of mesoporous silica nanoparticles: General aspects and in vitro toxicity. Adv Colloid Interface Sci. 2022; 307:102746. DOI: 10.1016/j.cis.2022.102746. View

Chen J, Ding H, Wang J, Shao L . Preparation and characterization of porous hollow silica nanoparticles for drug delivery application. Biomaterials. 2003; 25(4):723-7. DOI: 10.1016/s0142-9612(03)00566-0. View

Chen A, Zhang M, Wei D, Stueber D, Taratula O, Minko T . Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells. Small. 2009; 5(23):2673-7. PMC: 2833276. DOI: 10.1002/smll.200900621. View

Clegg A, Scott D, Hewitson P, Sidhu M, Waugh N . Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax. 2002; 57(1):20-8. PMC: 1746188. DOI: 10.1136/thorax.57.1.20. View

de la Harpe K, Kondiah P, Choonara Y, Marimuthu T, du Toit L, Pillay V . The Hemocompatibility of Nanoparticles: A Review of Cell-Nanoparticle Interactions and Hemostasis. Cells. 2019; 8(10). PMC: 6829615. DOI: 10.3390/cells8101209. View

10.

de Silva L, Fu J, Htar T, Wan Kamal W, Kasbollah A, Muniyandy S . Biodistribution Study of Niosomes in Tumor-Implanted BALB/C Mice Using Scintigraphic Imaging. Front Pharmacol. 2022; 12:778396. PMC: 8777053. DOI: 10.3389/fphar.2021.778396. View

11.

de Wilt L, Jansen G, Assaraf Y, Van Meerloo J, Cloos J, Schimmer A . Proteasome-based mechanisms of intrinsic and acquired bortezomib resistance in non-small cell lung cancer. Biochem Pharmacol. 2011; 83(2):207-17. DOI: 10.1016/j.bcp.2011.10.009. View

12.

Dilnawaz F . Multifunctional Mesoporous Silica Nanoparticles for Cancer Therapy and Imaging. Curr Med Chem. 2018; 26(31):5745-5763. DOI: 10.2174/0929867325666180501101044. View

13.

Dilnawaz F, Sahoo S . Enhanced accumulation of curcumin and temozolomide loaded magnetic nanoparticles executes profound cytotoxic effect in glioblastoma spheroid model. Eur J Pharm Biopharm. 2013; 85(3 Pt A):452-62. DOI: 10.1016/j.ejpb.2013.07.013. View

14.

Djayanti K, Maharjan P, Cho K, Jeong S, Kim M, Shin M . Mesoporous Silica Nanoparticles as a Potential Nanoplatform: Therapeutic Applications and Considerations. Int J Mol Sci. 2023; 24(7). PMC: 10094416. DOI: 10.3390/ijms24076349. View

15.

Fan Q, Wang Q, Cai R, Yuan H, Xu M . The ubiquitin system: orchestrating cellular signals in non-small-cell lung cancer. Cell Mol Biol Lett. 2020; 25:1. PMC: 6966813. DOI: 10.1186/s11658-019-0193-6. View

16.

Fukuda S, Pelus L . Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther. 2006; 5(5):1087-98. DOI: 10.1158/1535-7163.MCT-05-0375. View

17.

Gisbert-Garzaran M, Vallet-Regi M . Influence of the Surface Functionalization on the Fate and Performance of Mesoporous Silica Nanoparticles. Nanomaterials (Basel). 2020; 10(5). PMC: 7279540. DOI: 10.3390/nano10050916. View

18.

Groen K, van de Donk N, Stege C, Zweegman S, Nijhof I . Carfilzomib for relapsed and refractory multiple myeloma. Cancer Manag Res. 2019; 11:2663-2675. PMC: 6450182. DOI: 10.2147/CMAR.S150653. View

19.

Guan J, Sun J, Sun F, Lou B, Zhang D, Mashayekhi V . Hypoxia-induced tumor cell resistance is overcome by synergistic GAPDH-siRNA and chemotherapy co-delivered by long-circulating and cationic-interior liposomes. Nanoscale. 2017; 9(26):9190-9201. DOI: 10.1039/c7nr02663c. View

20.

Hajek R, Masszi T, Petrucci M, Palumbo A, Rosinol L, Nagler A . A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2016; 31(1):107-114. PMC: 5220126. DOI: 10.1038/leu.2016.176. View